SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of September
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82 -
|
EXHIBIT
NUMBER |
|
DESCRIPTION |
| |
|
|
| 99.1 |
|
News
Release Dated October 20, 2014 - Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with
Lincoln Park Capital Fund, LLC |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Oncolytics Biotech Inc.
(Registrant) |
| |
|
|
| |
|
|
| Date:
October 20, 2014 |
By: |
/s/ Kirk Look |
| |
|
Kirk Look |
| |
|
Chief Financial Officer |
Exhibit 99.1
Oncolytics Biotech® Inc. Announces Amendment to Common Share
Purchase Agreement with Lincoln Park Capital Fund, LLC
CALGARY, Oct. 20, 2014 /CNW/ - Oncolytics Biotech®
Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has reached an agreement
on amendments to its share purchase agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC")
dated February 27, 2014.
The specific amendments to the Agreement include allowing
the Company to sell shares to LPC at the Company's sole option independent of the closing price of the Common Stock, increasing
the number of shares that may be sold to LPC at certain price levels and changes to the way the number of Commitment Shares issuable
are calculated. In consideration of the amendments to the Agreement, the Company shall issue 146,397 shares of Common Stock to
LPC. All other terms and conditions of the Agreement remain in force without amendment.
"Amending our agreement with Lincoln Park provides us
with an option to incrementally access additional capital and better manage our balance sheet," said Dr. Brad Thompson, President
and CEO of Oncolytics. "This should allow us to maintain our focus on core operating initiatives in the quarters ahead."
The Company has filed a prospectus supplement, dated October
20, 2014, with respect to its U.S. registration statement on Form F-10 (the "Registration Statement") and Canadian final
base shelf prospectus (the "Base Shelf Prospectus"), each dated August 1, 2014, pursuant to which the Company may issue
up to US$3,900,000 of common shares pursuant to the terms of the Purchase Agreement (representing an aggregate market value of
not more than 10% of the market value of the Company's outstanding common shares based on the determination date under applicable
securities laws). Pursuant to the Purchase Agreement, the Company may file additional prospectus supplements in the United States
and in Canada in the future to qualify the sale of additional common shares to LPC that would result in aggregate gross proceeds
to the Company of up to US$26,000,000. No offers or sales of any common shares will be made in Canada pursuant to the Purchase
Agreement or the prospectus supplement.
The Company plans to use the net proceeds for working capital
and other general corporate purposes, including funding ongoing operations.
The common shares to be issued in the Financing have been
approved for listing on the NASDAQ. The Toronto Stock Exchange has accepted notice of the Financing and the Company is relying
on the section 602(g) exemption under the Toronto Stock Exchange Company Manual.
This news release shall not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of these common shares in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Oncolytics Biotech® Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
About Lincoln Park Capital
Lincoln Park Capital (LPC) is an institutional investor headquartered in Chicago, Illinois. LPC's experienced professionals manage
a portfolio of investments in public and private entities. These investments are in a wide range of companies and industries emphasizing
life sciences, specialty financing, energy and technology. LPC's investments range from multiyear financial commitments to fund
growth to special situation financings to long-term strategic capital offering companies certainty, flexibility and consistency.
For more information, please visit: www.lpcfunds.com.
This press release contains forward-looking statements
within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking
information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in
this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in
the future, including such things as the proposed offering of common shares and the intended use of proceeds and other such matters
are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking information.
Such risks and uncertainties include, among others, risks related to the market conditions of the offering and risks related to
the Company's business which may result in the intended use of proceeds changing. Investors should consult the Company's quarterly
and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating
to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking
statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking
information, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
%CIK: 0001129928
For further information:
TMX Equicom
Nick Hurst
300 5th Ave. SW, 10th Floor
Calgary, Alberta T2P 3C4
Tel: 403.218.2835
Fax: 403.218.2830
nhurst@tmxequicom.com
TMX Equicom
Michael Moore
San Diego, CA
Tel: 858.886.7813
mmoore@tmxequicom.com
Dian Griesel, Inc.
Susan Forman
335 West 38th Street, 3rd Floor
New York, NY 10018
Tel: 212.825.3210
Fax: 212.825.3229
sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 17:32e 20-OCT-14